Welcome to the e-CCO Library Archive!

Filter:
P354. The short health scale is a quick and reliable measure of health status in English speaking patients with Crohn's disease
P354

Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents

Authors:

D.T. Rubin*1, M. Skup2, S. Johnson3, J. Chao2, A. Gibofsky4

1University of Chicago , Medicine, Chicago, United States, 2AbbVie Inc., Global Health Economics & Outcomes Research, North Chicago, United States, 3Medicus Economics, LLC, , Milton, United States, 4Hospital for Special Surgery & Weill Cornell Medical College, , New York, United States

P355.

Safety and efficacy of restorative proctocolectomy in the elderly. A European, prospective, multicenter, S-ECCO study

Authors:

F. Colombo1, A. de Buck2, S. Sahami3, A. D'Hoore2, W. Bemelman3, Y. Panis4, G. Sampietro5, 1Luigi Sacco University Hosptal, Department of Surgery, Milano, Italy, 2University Hospitals Gasthuisberg, Department of Abdominal Surgery, Leuven, Belgium, 3Academic Medical Center, Surgery, Amsterdam, Netherlands, 4Hôpital Beaujon, Pole des Maladies de L'Appareil Digestif, Clichy, France, 5Luigi Sacco University Hospital. IBD Surgical Unit, Department of Surgery, Milano, Italy

P355. Efficacy and safety of oral tacrolimus for the treatment of severe steroid-resistant ulcerative colitis
P355. Prevalence of new serological markers in an old Irish IBD cohort
P355. The association between plasma histidine level and the efficacy of elemental diet therapy in Crohn's disease patients
Authors:

M. Nakano1, K. Tominaga1, M. Hoshino1, K. Kanke1, H. Hiraishi1, 1Dokkyo Medical University, Department of Gastroenterology, Mibu-machi, Japan

P355

What is treat-to-target of Crohn's Disease: the comparison of long-term outcome among patients with mucosal healing, deep remission and biological remission ?

Authors:

Y. Qiu*, R. Mao, B.-l. Chen, Y. He, Z.-r. Zeng, M.-h. Chen

First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P356.

Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist

Authors:

A. Olson1, J. Hartung2, G. Timony3, R. Peach4, M. Boehm5, H. Smith2, S. Gujrathi6, 1Receptos, Clinical Development, San Diego, United States, 2Receptos, Clinical Operations, San Diego, United States, 3Receptos, Preclinical Sciences, San Diego, United States, 4Receptos, CSO, San Diego, United States, 5Receptos, CTO, San Diego, United States, 6Receptos, CMO, San Diego, United States

P356. Irish IBD patients' perception of colorectal cancer screening: Lessons learnt from an 18 years follow up study
P356. Loss of efficacy and adverse drug reactions during infliximab therapy in IBD patients are related to the appearance of anti-infliximab antibodies
P356. The natural history of systemic corticosteroid therapy in ulcerative colitis: a nationwide, retrospective cohort from the Veterans Affairs healthcare system
Authors:

N. Khan1, A. Abbas2, A. Williamson2, L. Balart2, 1Southeast Louisiana Veterans Health Care System, Gastroenterology, New Orleans, United States, 2Tulane University, Gastroenterology, New Orleans, United States

P356

Durable Clinical Remission and Response in Adalimumab-Treated Patients with Ulcerative Colitis

Authors:

R. Panaccione*1, J.-F. Colombel2, W.J. Sandborn3, W. Reinisch4, 5, G. D'Haens6, D. Hommes7, S. Ghosh1, B. Pappalardo8, J. Petersson8, A.M. Robinson8, A. Lazar9, Q. Zhou8, R.B. Thakkar8

1University of Calgary, Department of Medicine, Calgary, Canada, 2Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States, 3University of California San Diego, Gastroenterology, La Jolla, CA, United States, 4McMaster University, Gastroenterology, Hamilton, Canada, 5Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, Austria, 6Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 7University of California, Gastroenterology, Los Angeles, CA, United States, 8AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States, 9AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

P357.

Role of THD in patients affected by Crohn's disease and haemorrhoidal disease: a preliminary study

Authors:

G. Giarratano1, A. Stazi1, C. Toscana2, L. Franceschilli3, A. Gaspari3, P. Sileri3, 1Clinica Madonna delle Grazie, Surgery, Velletri, Italy, 2Clinica Villa Tiberia, Surgery, Rome, Italy, 3University of Rome Tor Vergata, Department of Sperimental medicine and Surgery, Rome, Italy

P357. Clinical epidemiology of inflammatory bowel disease in a Libyan population
P357. The impact of peri-operative administration of infliximab on post-operative complication rates: a rat experimental study
Authors:

C. Zeglinas1, I. Papaconstantinou2, M. Gazouli3, C. Nastos2, A. Yiallourou2, C. Evagelou4, I. Vlahogiannakos5, K. Tsimaratou3, A. Papalois6, C. Tzathas1, 1Tzaneion, Gastroenterology, Piraeus, Greece, 2Areteion, Surgery, Athens, Greece, 3Molecular carcinigenesis group, Laboratory of Histology and Embryology, Athens, Greece, 4Medical School, Pathology, Athens, Greece, 5Laikon Hospital, Internal Medicine, Athens, Greece, 6Experimental-Research Unit, ELPEN-Pharmaceuticals Co. Inc, Pikermi, Greece

P357. Treatment practice for IBD-associated anaemia remains out of tune with recommendations – a two year follow-up survey in five European countries
P357

Integrated care pathways for Inflammatory Bowel Disease Surgery: Design and first analysis.

Authors:

R. Jacobs*1, 2, S. Reardon3, D. Sagar1, T.J. Hommes1, 2, D. Margolis4, E. Kane1, W.K. Van Deen1, L. Eimers1, E.K. Inserra1, N. Duran1, J.M. Choi1, C.Y. Ha1, B. Roth1, A.D. Ho1, E. Esrailian1, J. Sack3, D.W. Hommes1

1UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Los Angeles, United States, 2LUMC, Gastroenterology and Hepatology, Leiden, Netherlands, 3UCLA, Division of General Surgery, Los Angeles, United States, 4UCLA, Division of Radiological Sciences, Los Angeles, United States

P358.

Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years (GETAID survey)

Authors:

F. Poullenot1, P. Seksik2, L. Beaugerie2, A. Amiot3, M. Nachury4, V. Abitbol5, C. Stefanescu6, C. Reenaers7, M. Fumery8, A.-L. Pelletier9, S. Nancey10, L. Peyrin-Biroulet11, A. Bourreille12, X. Hebuterne13, H. Brixi14, G. Savoye15, N. Lourenco16, R. Altwegg17, G. Bommelaer18, C. Cazelles-Boudier19, A. Racine20, D. Laharie1, 1CHU de Bordeaux, Gastroenterologie, Pessac, France, 2Hopital Saint-Antoine – APHP, Gastroenterologie, Paris, France, 3Hôspital Henri-Mondor, Gastroenterologie, Creteil, France, 4CHU de Lille, Gastroenterologie, Lille, France, 5Hopital Cochin – APHP, Gastroenterologie, Paris, France, 6Hopital Beaujon – APHP, Gastroenterologie, Clichy, France, 7CHU de Liege, Gastroenterologie, Liege, Belgium, 8CHU de Amiens, Gastroenterologie, Amiens, France, 9Hopital Bichat – APHP, Gastroenterologie, Paris, France, 10Hopital Lyon Sud – APHL, Gastroenterologie, Pierre-Benite, France, 11CHU de Nancy, Gastroenterologie, Vandoeuvre-les-Nancy, France, 12CHU de Nantes, Gastroenterologie, Nantes, France, 13CHU de Nice, Gastroenterologie, Nice, France, 14CHU de Reims, Gastroenterologie, Reims, France, 15CHU de Rouen, Gastroenterologie, Rouen, France, 16Hopital Saint-Louis – APHP, Gastroenterologie, Paris, France, 17CHU de Montpellier, Gastroenterologie, Montpellier, France, 18CHU de Clermont-Ferrand, Gastroenterologie, Clermont-Ferrand, France, 19CH de Bayonne, Gastroenterologie, Bayonne, France, 20Hôpital du Kremlin-Bicetre – APHP, Gastroenterologie, Kremlin-Bicetre, France

P358. Environmental factors in infancy and ulcerative colitis in Chile: A case–control study
P358. Nodular regenerative hyperplasia due to thiopurines in patients with inflammatory bowel disease: Retrospective review in a hospital series